GlassScriptPhysician profile
Thomas Badin
NPI 1740358704
$3,564.69
in general payments reported to CMS, 2019-2025
22 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $110 · 2021: $195 · 2022: $449 · 2023: $370 · 2024: $489 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $373.18 | 2022-2024 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $270.53 | 2019 | |
| Abbvie INC. | $232.13 | 2019-2023 | Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $228.07 | 2019 | |
| Allergan, INC. | $227.59 | 2019 | |
| Merck Sharp & Dohme LLC | $227.49 | 2019-2024 | Capvaxive |
| Teva Pharmaceuticals USA, INC. | $212.03 | 2022 | |
| Edwards Lifesciences Corporation | $169.04 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $143.75 | 2025 | Spravato |
| Lilly USA, LLC | $142.15 | 2023-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Sumitomo Pharma America, INC. | $124.88 | 2024 | Gemtesa |
| Abbott Laboratories | $121.53 | 2019 | |
| Amgen INC. | $120.06 | 2019 | |
| Acadia Pharmaceuticals INC | $119.16 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $116.35 | 2019 | |
| Corcept Therapeutics | $114.37 | 2024 | Korlym |
| Pfizer INC. | $112.06 | 2019 | |
| Sanofi Pasteur INC. | $109.80 | 2020 | |
| Daiichi Sankyo INC. | $107.62 | 2019 | |
| Teleflex LLC | $98.12 | 2023 | Urolift |
| Boston Scientific Corporation | $69.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Badin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.